Clinical relevance of reduced bioavailability of rifampicin.
Joshi
S R
SR
D016907:Adverse Drug Reaction Reporting Systems; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D001682:Biological Availability; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D007194:India; D007538:Isoniazid / Q000008:administration & dosage / Q000009:adverse effects; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*
D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin